Clinical Research Directory
Browse clinical research sites, groups, and studies.
Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
Sponsor: Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Summary
CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.
Official title: Circadian Rhythm Impact on Triple Negative Breast Cancer Response to Neoadjuvant Immunotherapy - a Feasibility Randomized Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-09-01
Completion Date
2025-09-01
Last Updated
2025-03-19
Healthy Volunteers
No
Conditions
Interventions
Morning pembrolizumab infusions
Patients will be randomized 1:1 to receive all three neoadjuvant pembrolizumab cycles in the morning (before noon) or in the afternoon (after noon).
Locations (1)
Centro Hospitalar Vila Nova de Gaia/Espinho
Vila Nova de Gaia, Região, Portugal